Liver Cancer Care: Tracking Real-World Diagnoses and Treatments at Tongji Hospital

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational cohort study conducted at Tongji Hospital, aiming to build a real-world database of liver cancer patients. Researchers will systematically collect diagnostic information, treatments, and long-term outcomes to evaluate prognosis and treatment effectiveness in routine practice. Data will support evidence-based optimization of clinical decision-making for both primary and metastatic liver cancer. The study will include patients receiving liver resection, systemic therapy, and locoregional interventions, with follow-up aligned to standard care. No experimental interventions are mandated by the protocol beyond standard clinical management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female aged ≥18 years at the time of signing the informed consent form
* Clinically or histologically confirmed diagnosis of liver cancer
* Recieving treatment and follow-up in Tongji Hospital

Exclusion Criteria:

\- Refuse participanting in this study

Where it's running

• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Qi Cheng, M.D.
• Email: chengqi@hust.edu.cn
• Phone: 13871459541

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Risk-stratified approach to catching liver cancer earlier in people with chronic liver disease

  This study tests whether a standardized risk-based management plan can help diagnose liver cancer earlier in people who have chronic liver disease.

  Recruiting Shenzhen Third People's Hospital · Shenzhen, Guangdong · NCT07820644

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Combined multimodal tumor therapy system for liver cancer

  Aims to test a multimodal tumor treatment that combines thermal ablation with immune-based approaches for adults with primary or metastatic liver cancer who can’t have surgery.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07459309

• Italian registry of techniques to grow the liver before surgery

  This project will see how hospitals across Italy use different techniques to make the liver grow before surgery for adults with liver tumors.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT07445412

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Spectral CT during embolization and ablation for liver and kidney tumors

  This pilot tries a new spectral CT technique during image-guided embolization and ablation for adults with liver or kidney tumors to see if it improves image quality and helps guide treatment.

  Recruiting Palo Alto Veterans Institute for Research · Palo Alto, California · NCT07303725

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.